Terms: = Breast cancer AND SDHB, PGL4, 6390, ENSG00000117118, SDH1, SDHIP, SDH, IP AND Clinical Outcome
4 results:
1. TOP2A Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor clinical outcome?
Solhusløkk Höse K; Stenman A; Svahn F; Larsson C; Juhlin CC
Endocr Pathol; 2023 Mar; 34(1):129-141. PubMed ID: 36656469
[TBL] [Abstract] [Full Text] [Related]
2. Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents.
Miller IS; Shiels LP; Conroy E; Connor K; Dicker P; Gallagher WM; Donovan NO; Kerbel RS; Crown J; Byrne AT
Sci Rep; 2019 Jun; 9(1):9204. PubMed ID: 31235775
[TBL] [Abstract] [Full Text] [Related]
3. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC
Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720
[TBL] [Abstract] [Full Text] [Related]
4. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE
Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899
[TBL] [Abstract] [Full Text] [Related]
